H1N1 Vaccines Market - RegionalInsights
On the basis of geography, H1N1Vaccines Market is segmented into North America, Latin America, Europe,Asia Pacific, Middle East, and Africa. North America is expected to lead theH1N1 vaccines market during the forecast period. This is due to increasing governmentinitiatives for prevention of H1N1 infection. U.S. which faced major epidemicin 2009. After this pandemic the U.S. has strengthen the preventive approach tocontrol H1N1 outbreak by implementing vaccination program. According tostatistics given by Centre for Disease Control and Prevention in February 2018, during October 1, 2017 and February 3, 2018, clinical laboratoriestested 666,493 specimens for influenza virus, 124,316 (18.7%) of which testedpositive for influenza virus. 84.3% of these tested positive for influenza A.
Furthermore Asia Pacific marketis expected to exhibit the highest CAGR due to high prevalence of swine flu andincreasing awareness about vaccination against H1N1. According to Ministry ofHealth and Family Welfare, Government of India, there were 0.1 million cases inIndia of H1N1 influenza during 2010 to 2017. Continuous changing nature of thevirus creates challenges to overcome the H1N1 epidemic. For instance, in 2017new Michigan strain of H1N1 swine flu virus was first identified in India.Government has played an important role in tackling swine flu by spreadingawareness about H1N1 vaccine The Government of India has published guidelinesfor case management of influenza A/H1N1 which classifies influenza patients intothree categories depending on severity. Vaccination was recommended in patientgroup which are susceptible to H1N1 fever in future.
* The sample copy includes:Report Summary, Table of Contents, Segmentation, Competitive Landscape, ReportStructure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/2056
H1N1 influenza virus causes viraldisease, commonly known as swine flu, which mostly affects the respiratory system.Swine flu is characterized by infection from H1N1 strain. Symptoms of H1N1 fluare fever, cough, sore throat, runny or stuffy nose, watery and red eyes, bodyaches, headache, fatigue, and diarrhea. H1N1 spreads through contact withcontaminated air or geographical locations infected with virus. H1N1 infectionmay worsen other chronic respiratory conditions such as bronchitis, pneumonia,COPD, and sometimes even death due to respiratory failure.
H1N1 vaccine is an importantinnovation to tackle the H1N1 pandemic since 2009. Initially, the vaccinesdeveloped or available were inactivated monovalent vaccines that could preventinfection from most of the strains of H1N1. There are two routes ofadministration such as intradermal for inactivated vaccine and intranasal forlive attenuated vaccine. Both routes shown efficacy profile and arebioequivalent against preventing H1N1 infection. Global H1N1 vaccine market haspresence of both multinational pharmaceutical companies and companies fromemerging economies.
H1N1 Vaccines Market - MarketDynamics
One of the major factorpropelling growth of H1N1 market is increased incidence of disease and episodesof pandemic worldwide from H1N1 infection. According to World HealthOrganization’s (WHO) 2018, factsheet estimates, 290,000 to 650,000 deaths arereported each year from all types of influenza infection (including Influenza Ai.e. H1N1). Each year there are 3 to 5 million cases of severe illness fromviral influenza infection globally, according to the same source.
Browse ResearchReport: https://www.coherentmarketinsights.com/ongoing-insight/h1n1-vaccines-market-2056
Government initiatives, bothinternationally and nationally, to tackle H1N1 pandemic would positively impactthe market growth. Health institution such as World Health Organization (WHO)have been instrumental in developing vaccines and supporting efficientdistribution of the vaccine. After 2009 pandemic of H1N1 influenza, the U.S.government initiated US$ 3 billion H1N1 vaccine project under which itcontracted five major companies to develop vaccine for H1N1 influenza. Underthe WHO’s Global Influenza Surveillance and Response System, National InfluenzaCenters and WHO Collaborating Centers are continuously monitoring the influenzaviruses circulating in humans and updates the composition of influenza vaccinestwice a year.
Furthermore, rising geriatricpopulation worldwide would be another impetus for growth of the H1N1 vaccinemarket. Global population is crossing the age of 60 at annual rate of 3%according to 2017 UN report. Increased age, maximizes the risk of variousrespiratory tract related diseases and immune deficient diseases, thereby therisk for infection due to H1N1 virus rises. Awareness amongst patients aboutpreventive healthcare approaches such as vaccination may lead to higher demandfor H1N1 vaccines during forecast period.
However, seasonal nature ofoccurrence of H1N1 flu has led to meagre revenue for many of the key players.For instance, India-based Serum Institute, which produces intranasal livevaccine to treat swine flu had to destroy stock of 2 million doses in the year 2011due to lack of demand. In contrast, if pandemic arises suddenly, supply ofvaccine may be delayed due to slow production of vaccine, which may negativelyaffect health of many patients. Due to constant evolving nature of H1N1 virus,vaccine may prove to be ineffective in some parts of the world, which may deterthe use of vaccines.
H1N1 Vaccines Market -Competitive Landscape
Key players present in the H1N1vaccines market are Medimmune, AstraZeneca, GlaxoSmithKline, Novartis, SerumInstitute of India, Abbott Healthcare, Sanofi Pasture, CSL Biotherapeutics,Sinovac, ID Biomedical Corporation, Cadila Healthcare, and Lupin Ltd.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/2056
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
